Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.
Galimberti S, Ciabatti E, Ercolano G, Grassi S, Guerrini F, Cecconi N, Rousseau M, Cervetti G, Mazziotta F, Iovino L, Falzetti F, Falcinelli F, Bosi A, Rigacci L, Kovalchuk S, Vallisa D, Macchia L, Ciancia E, Petrini M. Galimberti S, et al. Among authors: grassi s. Front Pharmacol. 2017 Jun 29;8:413. doi: 10.3389/fphar.2017.00413. eCollection 2017. Front Pharmacol. 2017. PMID: 28706485 Free PMC article.
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia.
Galimberti S, Grassi S, Baratè C, Guerrini F, Ciabatti E, Perutelli F, Ricci F, Del Genio G, Montali M, Barachini S, Giuliani C, Ferreri MI, Valetto A, Abruzzese E, Ippolito C, Iurlo A, Bocchia M, Sicuranza A, Martino B, Iovino L, Buda G, Salehzadeh S, Petrini M, Di Paolo A, Mattii L. Galimberti S, et al. Among authors: grassi s. Front Oncol. 2018 Dec 6;8:555. doi: 10.3389/fonc.2018.00555. eCollection 2018. Front Oncol. 2018. PMID: 30574454 Free PMC article.
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia.
Grassi S, Palumbo S, Mariotti V, Liberati D, Guerrini F, Ciabatti E, Salehzadeh S, Baratè C, Balducci S, Ricci F, Buda G, Iovino L, Mazziotta F, Ghio F, Ercolano G, Di Paolo A, Cecchettini A, Baldini C, Mattii L, Pellegrini S, Petrini M, Galimberti S. Grassi S, et al. Front Oncol. 2019 Jun 24;9:532. doi: 10.3389/fonc.2019.00532. eCollection 2019. Front Oncol. 2019. PMID: 31293972 Free PMC article.
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
Della Starza I, Cavalli M, De Novi LA, Genuardi E, Mantoan B, Drandi D, Barbero D, Ciabatti E, Grassi S, Gazzola A, Mannu C, Agostinelli C, Piccaluga PP, Bomben R, Degan M, Gattei V, Guarini A, Foà R, Galimberti S, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network. Della Starza I, et al. Among authors: grassi s. Hematol Oncol. 2019 Oct;37(4):368-374. doi: 10.1002/hon.2652. Epub 2019 Aug 16. Hematol Oncol. 2019. PMID: 31325190
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis.
Genuardi E, Barbero D, Dogliotti I, Mantoan B, Drandi D, Gambella M, Zaccaria GM, Monitillo L, Della Starza I, Cavalli M, De Novi LA, Ciabatti E, Grassi S, Gazzola A, Mannu C, Del Giudice I, Galimberti S, Agostinelli C, Piccaluga PP, Ladetto M, Ferrero S; Fondazione Italiana Linfomi (FIL) MRD Network. Genuardi E, et al. Among authors: grassi s. Int J Lab Hematol. 2018 Apr;40(2):201-208. doi: 10.1111/ijlh.12766. Epub 2017 Dec 4. Int J Lab Hematol. 2018. PMID: 29205868
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M. Galimberti S, et al. Among authors: grassi s. Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14. Clin Cancer Res. 2014. PMID: 25316810 Free article.
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.
Guerrini F, Paolicchi M, Ghio F, Ciabatti E, Grassi S, Salehzadeh S, Ercolano G, Metelli MR, Del Re M, Iovino L, Petrini I, Carulli G, Cecconi N, Rousseau M, Cervetti G, Galimberti S. Guerrini F, et al. Among authors: grassi s. Front Pharmacol. 2016 Oct 13;7:363. doi: 10.3389/fphar.2016.00363. eCollection 2016. Front Pharmacol. 2016. PMID: 27790140 Free PMC article.
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.
Salehzadeh S, Guerrini F, Pizzano U, Grassi S, Ciabatti E, Iovino L, Buda G, Caracciolo F, Benedetti E, Orciuolo E, Pelosini M, Consani G, Carulli G, Metelli MR, Martini F, Mazziotta F, Mazzantini E, Rossi P, Tavarozzi R, Ricci F, Petrini M, Galimberti S. Salehzadeh S, et al. Among authors: grassi s. Cancer Cell Int. 2019 Apr 4;19:83. doi: 10.1186/s12935-019-0807-0. eCollection 2019. Cancer Cell Int. 2019. PMID: 30992690 Free PMC article.
Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients.
Grassi S, Guerrini F, Ciabatti E, Puccetti R, Salehzadeh S, Metelli MR, Di Vita A, Domenichini C, Caracciolo F, Orciuolo E, Pelosini M, Mazzantini E, Rossi P, Mazziotta F, Petrini M, Galimberti S. Grassi S, et al. Cancers (Basel). 2020 Jun 30;12(7):1738. doi: 10.3390/cancers12071738. Cancers (Basel). 2020. PMID: 32629801 Free PMC article.
308 results